Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,138.10 +100.88 0.67%
Hang Seng 23,082.70 +38.44 0.17%
S&P/ASX 200 5,180.77 +15.11 0.29%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

United Therapeutics Corp

+ Add to Watchlist

UTHR:US

69.1700 USD 0.6900 1.01%

As of 20:10:00 ET on 05/17/2013.

Company Profile for United Therapeutics Corp (UTHR)

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

Contact Information

United Therapeutics Corp

1040 Spring Street
Silver Spring, MD 20910
United States
Phone: 1-301-608-9292
Fax: 1-301-608-9291

Key Executives for United Therapeutics Corp (UTHR)

Martine A RothblattChairman/CEO/FounderRoger A JeffsPresident/COO
John M FerrariCFO/TreasurerPaul A MahonExec VP/Secy/General Counsel

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil